Sensitivity to Intravenous Nicotine: Genetic Moderators
What is the purpose of this trial?
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.
- 18 Years - 50 Years
- National Institute on Drug Abuse (NIDA)
- June 2009
- Last Updated:
- June 13, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT00969137